secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2024-01-31T23:59:59+00:00
Accession:  0000950170-24-009147
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Agenus receives $25M milestone payment from Bristol Myers Squibb for BMS-986442 trial progress
--------------------------------------------------------------------------------

- $25M payment received Jan 30, 2024, under global licensing agreement with BMS.
- Triggered by dosing of first patient in phase 2 dose expansion of CA115-001 trial of BMS-986442.
- This is the second development milestone under the agreement; first achieved previously.
- Payment was received on January 30, 2024, as confirmed by the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000095017024009147/0000950170-24-009147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000095017024009147/agen-20240130.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-009147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer